New Amsterdam Pharma
Chris Deluzio serves as the Executive Vice President of Enterprise Operations at NewAmsterdam Pharma since September 2023, focusing on developing operational infrastructure. Prior to this role, Chris held prominent positions at Biohaven Pharmaceuticals from June 2019 to March 2023, including SVP of Biohaven Enterprise Operations and as the commercial integration lead following Biohaven's acquisition by Pfizer in October 2022. Chris's extensive experience also includes leadership roles at Takeda, AstraZeneca, Boehringer Ingelheim, Sunovion Pharmaceuticals, JHP Pharmaceuticals, NitroMed, Ethicon, and Bristol-Myers Squibb, with a consistent focus on sales, commercial operations, and training. Chris holds a Bachelor of Arts from Rutgers University and a Master of Science from the University of Pennsylvania.
This person is not in any offices
New Amsterdam Pharma
1 followers
Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.